Want to see CYTOF full AI Analyst Report?
CYTOF Stock Chart & Stats
$0.05
$0.00(0.00%)
At close: 4:00 PM EDT
$0.05
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$0.05 - $0.15
Previous CloseN/A
Volume1.00
Average Volume (3M)8.02K
Market Cap
$443.21K
Enterprise Value$1.14M
Total Cash (Recent Filing)$49.57K
Total Debt (Recent Filing)$3.47M
Price to Earnings (P/E)―
Beta2.13
Next Earnings
Sep 09, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-228.63
Shares Outstanding5,715,472
10 Day Avg. Volume7,440
30 Day Avg. Volume8,018
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap2.57
Enterprise Value/Revenue-3.22
Enterprise Value/Gross Profit-1.65
Enterprise Value/Ebitda0.56
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-1.61
Revenue Forecast (FY)$5.15M
Bulls Say, Bears Say
Bulls Say
Equity ImprovementThe improvement in equity indicates a strengthening financial position, which can enhance investor confidence and provide a foundation for future growth initiatives.
Proprietary Technology PlatformsProprietary technology platforms can provide a competitive edge in the biotechnology sector, enabling the development of unique treatments and potential market leadership.
Strategic AlliancesStrategic alliances and collaborations can enhance Altamira's research capabilities, provide financial support, and accelerate the development and commercialization of its therapies.
Bears Say
Negative Cash FlowPersistent negative cash flow can strain the company's liquidity, limiting its ability to invest in growth opportunities and potentially necessitating additional funding.
Declining RevenueDeclining revenue trends suggest challenges in product adoption or market penetration, which could hinder long-term growth and profitability prospects.
Operational InefficienciesOperational inefficiencies and negative profit margins indicate challenges in cost management, which can impact the company's ability to achieve sustainable profitability.
Altamira Therapeutics News
CYTOF FAQ
What was Altamira Therapeutics’s price range in the past 12 months?
Altamira Therapeutics lowest stock price was $0.05 and its highest was $0.15 in the past 12 months.
What is Altamira Therapeutics’s market cap?
Altamira Therapeutics’s market cap is $443.21K.
When is Altamira Therapeutics’s upcoming earnings report date?
Altamira Therapeutics’s upcoming earnings report date is Sep 09, 2026 which is in 35 days.
How were Altamira Therapeutics’s earnings last quarter?
Altamira Therapeutics released its earnings results on Mar 31, 2026. The company reported -$0.246 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.246.
Is Altamira Therapeutics overvalued?
According to Wall Street analysts Altamira Therapeutics’s price is currently Overvalued.
Does Altamira Therapeutics pay dividends?
Altamira Therapeutics does not currently pay dividends.
What is Altamira Therapeutics’s EPS estimate?
Altamira Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Altamira Therapeutics have?
Altamira Therapeutics has 5,715,472 shares outstanding.
What happened to Altamira Therapeutics’s price movement after its last earnings report?
Altamira Therapeutics reported an EPS of -$0.246 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Altamira Therapeutics?
Currently, no hedge funds are holding shares in CYTOF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Altamira Therapeutics
Auris Medical Holding Ltd. engages in the development of novel products that address unmet medical needs in neurotology and central nervous system disorders. The firm focuses on the development of intranasal betahistine for the treatment of vertigo and for the prevention of antipsychotic-induced weight gain and somnolence. It also includes other programs under development such as Keyzilen, for the treatment of acute inner ear tinnitus; and Sonsuvi, for the treatment of acute inner ear hearing loss. The company was founded by Thomas Meyer in April 2003 and is headquartered in Hamilton, Bermuda.
Technical Analysis
Biodexa Pharmaceuticals
―
Q/C Technologies
―
―
Scinai Immunotherapeutics
―
Oragenics
―